Edoardo Ferlazzo, Dorothee Kasteleijn-Nolst Trenite, Gerrit-Jan de Haan, Felix Felix Nitschke, Saija Ahonen, Sara Gasparini, Berge A Minassian
BACKGROUND: Progressive myoclonus epilepsies (PMEs) are a group of rare inherited diseases featuring a combination of myoclonus, seizures and variable degree of cognitive impairment. Despite extensive investigations, a large number of PMEs remain undiagnosed. In this review, we focus on the current pharmacological approach to PMEs.
METHODS: References were mainly identified through PubMed search until February 2017 and backtracking of references in pertinent studies.
RESULTS: The majority of available data on the efficacy of antiepileptic medications in PMEs are primarily anecdotal or observational, based on individual responses in small series. Valproic acid is the drug of choice, except for PMEs due to mitochondrial diseases. Levetiracetam and clonazepam should be considered as the first add-on treatment. Zonisamide and perampanel represent promising alternatives. Phenobarbital and primidone should be reserved to patients with resistant disabling myoclonus or seizures. Lamotrigine should be used with caution due to its unpredictable effect on myoclonus. Avoidance of drugs known to aggravate myoclonus and seizures, such as carbamazepine and phenytoin, is paramount. Psychiatric (in particular depression) and other comorbidities need to be adequately managed. Although a 3- to 4-drug regimen is often necessary to control seizures and myoclonus, particular care should be paid to avoid excessive pharmacological load and neurotoxic side effects. Target therapy is possible only for a minority of PMEs.
CONCLUSIONS: Overall, the treatment of PMEs remains symptomatic (i.e. pharmacological treatment of seizures and myoclonus). Further dissection of the genetic background of the different PMEs might hopefully help in the future with individualised treatment options.
Neuropsychiatr Dis Treat. 2015 Nov 30;11:2967-73
[PMID:
26664121]
Epilepsia. 2016 Feb;57(2):210-21
[PMID:
26666500]
Epilepsy Behav. 2009 Mar;14(3):545-9
[PMID:
19185615]
Ann Neurol. 1997 Oct;42(4):613-21
[PMID:
9382473]
Epileptic Disord. 2008 Mar;10(1):31-4
[PMID:
18367429]
Epilepsia. 2008 Apr;49(4):549-56
[PMID:
18325013]
Brain. 1989 Jun;112 ( Pt 3):765-77
[PMID:
2499399]
Neurology. 2006 May 23;66(10):1574-6
[PMID:
16717223]
Neurology. 2007 Sep 4;69(10 ):1027-34
[PMID:
17785672]
Ther Adv Neurol Disord. 2011 Jan;4(1):47-62
[PMID:
21339907]
Arch Neurol. 1982 Apr;39(4):236-8
[PMID:
6803743]
Acta Paediatr. 2006 Mar;95(3):312-7
[PMID:
16497642]
Neurology. 2015 Apr 14;84(15):1529-36
[PMID:
25770194]
Epilepsy Res. 2016 Mar;121:47-54
[PMID:
26875109]
Neurology. 2009 Apr 7;72(14):1279-80
[PMID:
19349610]
Pharm World Sci. 2007 Jun;29(3):164-6
[PMID:
17242859]
Neurology. 2014 Feb 4;82(5):405-11
[PMID:
24384641]
Epileptic Disord. 2012 Jun;14(2):155-8
[PMID:
22569507]
Nat Genet. 2015 Jan;47(1):39-46
[PMID:
25401298]
J Neurol Neurosurg Psychiatry. 1998 Mar;64(3):344-8
[PMID:
9527146]
Hum Mol Genet. 2014 Jun 15;23 (12 ):3147-56
[PMID:
24452334]
Epilepsy Res. 2009 Apr;84(2-3):201-9
[PMID:
19268538]
Epilepsia. 1999 Jun;40(6):796-9
[PMID:
10368082]
Mov Disord. 2010 Mar 15;25(4):520-1
[PMID:
20155865]
Epilepsia. 1995 Aug;36(8):783-91
[PMID:
7543407]
Parkinsonism Relat Disord. 2005 Mar;11(2):135-7
[PMID:
15734675]
Epilepsia. 2005;46 Suppl 9:67-72
[PMID:
16302877]
Epilepsia. 2001 May;42(5):692-701
[PMID:
11380581]
Expert Opin Pharmacother. 2017 Feb;18(2):187-193
[PMID:
28067060]
Epileptic Disord. 2016 Sep 1;18(S2):38-62
[PMID:
27702709]
Neurology. 1990 Sep;40(9):1412-6
[PMID:
2118240]
Ann Neurol. 1990 Jul;28(1):113-6
[PMID:
2115761]
Epileptic Disord. 2014 Jun;16(2):191-5
[PMID:
24777117]
J Pediatr. 2001 Apr;138(4):539-47
[PMID:
11295718]
Epilepsia. 2015 Jun;56(6):924-32
[PMID:
25963722]
Acta Medica (Hradec Kralove). 2013;56(1):36-8
[PMID:
23909054]
Epilepsy Behav Case Rep. 2013 Aug 16;1:118-21
[PMID:
25667843]
Epilepsy Behav Case Rep. 2014 Sep 29;2:164-6
[PMID:
25667898]
Neurology. 2004 Feb 24;62(4):640-3
[PMID:
14981187]
Lancet Neurol. 2005 Apr;4(4):239-48
[PMID:
15778103]
Arch Neurol. 2001 May;58(5):781-6
[PMID:
11346373]
Brain Dev. 2012 May;34(5):368-71
[PMID:
21889282]
Epilepsy Res. 1996 Nov;25(3):225-30
[PMID:
8956920]
Ann Neurol. 2008 Nov;64(5):514-22
[PMID:
19067373]
Epilepsia. 1980 Aug;21(4):351-7
[PMID:
6772434]
Epilepsia. 2006 May;47(5):860-6
[PMID:
16686650]
N Engl J Med. 1986 Jul 31;315(5):296-305
[PMID:
3088452]
Mov Disord. 2011 Feb 1;26(2):341-3
[PMID:
20939070]
Pediatr Res. 1993 Sep;34(3):281-7
[PMID:
8134167]
Epilepsy Res. 2007 Mar;73(3):219-27
[PMID:
17158032]
Epilepsia. 2004 Jun;45(6):678-81
[PMID:
15144434]
Pharmacopsychiatry. 1999 Mar;32 Suppl 1:49-53
[PMID:
10338109]
Neurology. 2003 Apr 22;60(8):1394-5
[PMID:
12707458]
Muscle Nerve. 2005 Feb;31(2):157-74
[PMID:
15547927]
Epilepsy Behav. 2005 Mar;6(2):260-3
[PMID:
15710314]
J Neurol Sci. 2006 Apr 15;243(1-2):97-9
[PMID:
16414077]
Epilepsia. 2006 Dec;47(12):2083-5
[PMID:
17201707]
Neurology. 2001 Sep 25;57(6):1112-4
[PMID:
11571347]
J Child Neurol. 1995 Jan;10(1):68-70
[PMID:
7769184]
Lancet. 1983 Oct 8;2(8354):838-42
[PMID:
6137660]
Mov Disord. 2011 Dec;26(14):2573-5
[PMID:
22025266]
Acta Neurol Scand. 1981 Aug;64(2):132-41
[PMID:
6172951]
Epilepsy Behav. 2016 Sep;62:132-5
[PMID:
27459034]
Pediatr Neurol. 2002 Jan;26(1):55-60
[PMID:
11814737]
Muscle Nerve. 2007 Feb;35(2):235-42
[PMID:
17080429]
Epileptic Disord. 2016 Sep 1;18(S2):145-153
[PMID:
27629998]
Epilepsia. 2017 Apr;58(4):543-547
[PMID:
28166365]
Seizure. 2014 Aug;23(7):512-20
[PMID:
24766826]
Orphanet J Rare Dis. 2016 Apr 16;11:40
[PMID:
27083890]
Hum Gene Ther. 2008 May;19(5):463-74
[PMID:
18473686]
Adv Neurol. 2005;95:307-23
[PMID:
15508934]
Curr Opin Pediatr. 2005 Aug;17 (4):519-24
[PMID:
16012266]
PLoS Genet. 2011 Apr;7(4):e1002037
[PMID:
21552327]
Philos Trans R Soc Lond B Biol Sci. 2003 May 29;358(1433):961-6
[PMID:
12803930]
Drug Des Devel Ther. 2015 Oct 19;9:5719-25
[PMID:
26543353]
Mov Disord. 1993;8(1):63-8
[PMID:
8419809]
Epilepsy Res. 1998 Jan;29(2):109-14
[PMID:
9477142]
